Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Gustave Roussy, Cancer Campus, Grand Paris33 enrolled

Overview

This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs' girdle.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sarcoma of Pelvis

Interventions

Tasonermine (TNFa)DRUG

MelphalanDRUG

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Soft tissue or bone sarcomas locally advanced of the pelvis or limbs' girdle Exclusion Criteria: * Resectable tumor without mutilation

Locations (1)

Institut Gustave-Roussy

Villejuif, France

RECRUITING

Outcomes

Primary Outcomes

Complete response rate on MRI

Secondary Outcomes

Histological response

Objective responses

Rate of conservative treatments

Overall survival and disease free survival

Local and systemic toxicity

Central Contacts

Sylvie Bonvalot, MD

CONTACT

33 1 42 11 363 bonvalot@igr.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.